Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244

Abstract

In a large, randomized trial, the efficacies of Stanford V and ABVD were comparable when given in combination with appropriate radiotherapy.

Prognostic factors for advanced‐stage human immunodeficiency virus‐associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi‐institutional retrospective study

“…It is noteworthy that the CR rate to ABVD observed in our cohort was comparable to the response rates to ABVD reported in immunocompetent HL patients with advanced-stage disease. 3,4,22 After a median follow-up of approximately 5 years, the patients in our cohort had 5-year PFS and OS rates of 69% and 78%, respectively. In the study by Spina et al, 21 patients experienced 3-year freedom from progression and OS rates of 60% and 51%, respectively, and the study by Montoto et al produced 5-year event-free survival and OS rates of 59% and 88%, respectively.…”

“…The 5-year PFS and OS rates in our cohort also were comparable to the survival rates reported in immunocompetent patients with advanced-stage HL. 3,4,22 Few studies have previously analyzed the prognostic value of the CD4-positive cell count. In the study by Hentrich et al, a CD4-positive count <200 cells/lL was not associated with PFS or OS after adjusting for covariates.…”

Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

“…ISRT (30-36 Gy; within 2-3 weeks after completion of chemotherapy) to initial sites >5 cm and involved spleen is recommended for patients with a Deauville score of 1 to 4 and for those with a Deauville score of 5 with a negative biopsy. 61,62 Patients with a positive biopsy should be managed as described for refractory disease.…”

“…RT was administered in both arms to sites of previous bulky sites (>5 cm) and to splenic deposits. 62 At the median follow-up of 4.3 years, the ORR, 5-year PFS, and 5-year OS rates were 91%, 76%, and 90%, respectively, for ABVD and 92%, 74%, and 92%, respectively, for Stanford V.…”

“…[60][61][62] In the Memorial Sloan Kettering Cancer Center study, 126 patients with either locally extensive or advanced disease were treated with the 12-week Stanford V chemotherapy regimen followed by 36 Gy of IFRT to bulky sites (≥5 cm) and/or to macroscopic splenic disease, 61 with 5-and 7-year OS rates of 90% and 88%, respectively. Of the patients for whom the Stanford V regimen failed, 58% underwent successful second-line therapy with high-dose therapy and autologous stem cell rescue (HDT/ASCR).…”